IMR Press / CEOG / Volume 26 / Issue 2 / pii/1999025

Clinical and Experimental Obstetrics & Gynecology (CEOG) is published by IMR Press from Volume 47 Issue 1 (2020). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with S.O.G.

Original Research

Ovarian stimulation using a new highly purified urinary FSH: a prospective randomized clinical study

Show Less
1 Gynecological and Obstetric Institute, University of Perugia (Italy)
2 Physiopathology of Human Reproduction Department, “Papardo” Hospital, Messina (Italy)
3 Associationfor Infertility Studies, Rome (Italy)
Clin. Exp. Obstet. Gynecol. 1999, 26(2), 93–94;
Published: 10 June 1999

The aim of this study was to determine the effectiveness of a new highly purified urinary FSH. A total of 60 in vitro-fertilization (IVF) patients, undergoing embryo transfer (ET) for the first time, were randomly allocated into two groups: Group A (n = 30). Subcutaneous administration of urinary follicle-stimulating hormone (FSH, Fostimon 75, A.M.S.A., Italy). Group B (n = 30). Subcutaneous administration of urinary follicle-stimulating hormone (FSH, Metrodin 75 HP, Serono, Italy). Statistical analysis was performed using the chi-square test, p < 0.05 was assumed as significant. This prospective randomized clinical study in an IVF-ET program showed that both drugs were equally safe and effective. Except for the number of the high quality embryos (3.16 vs 2.9; p = 0.03) the two groups did not differ in stimulation parameters or clinical pregnancy rates per attempt and per transfer. On the other hand, a mean number of 3.56 vs 2.18 embryos were cryopreserved in group A and in group B, respecti­vely, as a result of the high number of mature oocytes and high quality embryos. When frozen embryo cycles were included, the difference in pregnancy rate became significant.

Metrodin HP
Back to top